vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and SS&C Technologies Holdings Inc (SSNC). Click either name above to swap in a different company.
SS&C Technologies Holdings Inc is the larger business by last-quarter revenue ($1.6B vs $346.4M, roughly 4.8× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs 13.7%, a 14.4% gap on every dollar of revenue. On growth, SS&C Technologies Holdings Inc posted the faster year-over-year revenue change (8.8% vs 4.8%). Over the past eight quarters, SS&C Technologies Holdings Inc's revenue compounded faster (6.5% CAGR vs 1.5%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
SS&C Technologies Holdings, Inc. is an American multinational holding company headquartered in Windsor, Connecticut, that sells software and software as a service to the financial services industry. The company has offices in the Americas, Europe, Asia, Africa and Australia.
HAE vs SSNC — Head-to-Head
Income Statement — Q4 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $346.4M | $1.6B |
| Net Profit | $97.3M | $226.1M |
| Gross Margin | 57.2% | 48.7% |
| Operating Margin | 36.1% | 24.2% |
| Net Margin | 28.1% | 13.7% |
| Revenue YoY | 4.8% | 8.8% |
| Net Profit YoY | — | 6.2% |
| EPS (diluted) | — | $0.91 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $346.4M | $1.6B | ||
| Q4 25 | $339.0M | $1.7B | ||
| Q3 25 | $327.3M | $1.6B | ||
| Q2 25 | $321.4M | $1.5B | ||
| Q1 25 | $330.6M | $1.5B | ||
| Q4 24 | $348.5M | $1.5B | ||
| Q3 24 | $345.5M | $1.5B | ||
| Q2 24 | $336.2M | $1.5B |
| Q1 26 | $97.3M | $226.1M | ||
| Q4 25 | $44.7M | $193.1M | ||
| Q3 25 | $38.7M | $210.0M | ||
| Q2 25 | $34.0M | $180.8M | ||
| Q1 25 | $58.0M | $213.0M | ||
| Q4 24 | $37.5M | $248.2M | ||
| Q3 24 | $33.8M | $164.4M | ||
| Q2 24 | $38.4M | $190.3M |
| Q1 26 | 57.2% | 48.7% | ||
| Q4 25 | 59.7% | 47.8% | ||
| Q3 25 | 59.5% | 47.7% | ||
| Q2 25 | 59.8% | 48.0% | ||
| Q1 25 | 58.4% | 49.3% | ||
| Q4 24 | 55.5% | 49.3% | ||
| Q3 24 | 54.2% | 48.0% | ||
| Q2 24 | 52.0% | 48.1% |
| Q1 26 | 36.1% | 24.2% | ||
| Q4 25 | 19.9% | 22.3% | ||
| Q3 25 | 17.9% | 23.3% | ||
| Q2 25 | 16.8% | 22.4% | ||
| Q1 25 | 21.6% | 23.6% | ||
| Q4 24 | 16.9% | 23.4% | ||
| Q3 24 | 15.0% | 22.2% | ||
| Q2 24 | 11.8% | 22.6% |
| Q1 26 | 28.1% | 13.7% | ||
| Q4 25 | 13.2% | 11.7% | ||
| Q3 25 | 11.8% | 13.4% | ||
| Q2 25 | 10.6% | 11.8% | ||
| Q1 25 | 17.5% | 14.1% | ||
| Q4 24 | 10.8% | 16.2% | ||
| Q3 24 | 9.8% | 11.2% | ||
| Q2 24 | 11.4% | 13.1% |
| Q1 26 | — | $0.91 | ||
| Q4 25 | $0.95 | $0.76 | ||
| Q3 25 | $0.81 | $0.83 | ||
| Q2 25 | $0.70 | $0.72 | ||
| Q1 25 | $1.17 | $0.84 | ||
| Q4 24 | $0.74 | $0.98 | ||
| Q3 24 | $0.66 | $0.65 | ||
| Q2 24 | $0.74 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $245.4M | $420.9M |
| Total DebtLower is stronger | $1.2B | $7.4B |
| Stockholders' EquityBook value | $796.3M | $6.9B |
| Total Assets | $2.4B | $20.3B |
| Debt / EquityLower = less leverage | 1.53× | 1.08× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $245.4M | $420.9M | ||
| Q4 25 | $363.4M | $462.1M | ||
| Q3 25 | $296.4M | $388.3M | ||
| Q2 25 | $292.9M | $480.3M | ||
| Q1 25 | $306.8M | $515.0M | ||
| Q4 24 | $320.8M | $567.1M | ||
| Q3 24 | $299.3M | $694.7M | ||
| Q2 24 | $344.4M | $462.7M |
| Q1 26 | $1.2B | $7.4B | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $796.3M | $6.9B | ||
| Q4 25 | $911.5M | $6.9B | ||
| Q3 25 | $849.2M | $6.9B | ||
| Q2 25 | $882.3M | $6.9B | ||
| Q1 25 | $820.8M | $6.8B | ||
| Q4 24 | $906.9M | $6.5B | ||
| Q3 24 | $878.9M | $6.8B | ||
| Q2 24 | $905.4M | $6.4B |
| Q1 26 | $2.4B | $20.3B | ||
| Q4 25 | $2.5B | $20.7B | ||
| Q3 25 | $2.4B | $19.5B | ||
| Q2 25 | $2.5B | $19.0B | ||
| Q1 25 | $2.5B | $20.4B | ||
| Q4 24 | $2.5B | $19.0B | ||
| Q3 24 | $2.5B | $18.4B | ||
| Q2 24 | $2.5B | $16.9B |
| Q1 26 | 1.53× | 1.08× | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $293.2M | $299.7M |
| Free Cash FlowOCF − Capex | $209.9M | — |
| FCF MarginFCF / Revenue | 60.6% | — |
| Capex IntensityCapex / Revenue | 9.5% | 0.0% |
| Cash ConversionOCF / Net Profit | 3.01× | 1.33× |
| TTM Free Cash FlowTrailing 4 quarters | $417.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $293.2M | $299.7M | ||
| Q4 25 | $93.6M | $643.5M | ||
| Q3 25 | $111.3M | $456.2M | ||
| Q2 25 | $17.4M | $372.9M | ||
| Q1 25 | $116.6M | $272.2M | ||
| Q4 24 | $43.8M | $486.6M | ||
| Q3 24 | $48.8M | $336.6M | ||
| Q2 24 | $-27.4M | $384.9M |
| Q1 26 | $209.9M | — | ||
| Q4 25 | $87.2M | $633.0M | ||
| Q3 25 | $106.3M | $421.5M | ||
| Q2 25 | $13.6M | $350.0M | ||
| Q1 25 | $100.9M | $259.5M | ||
| Q4 24 | $35.2M | $466.9M | ||
| Q3 24 | $39.4M | $310.7M | ||
| Q2 24 | $-33.1M | $374.9M |
| Q1 26 | 60.6% | — | ||
| Q4 25 | 25.7% | 38.3% | ||
| Q3 25 | 32.5% | 26.9% | ||
| Q2 25 | 4.2% | 22.8% | ||
| Q1 25 | 30.5% | 17.1% | ||
| Q4 24 | 10.1% | 30.5% | ||
| Q3 24 | 11.4% | 21.2% | ||
| Q2 24 | -9.8% | 25.8% |
| Q1 26 | 9.5% | 0.0% | ||
| Q4 25 | 1.9% | 0.6% | ||
| Q3 25 | 1.5% | 2.2% | ||
| Q2 25 | 1.2% | 1.5% | ||
| Q1 25 | 4.7% | 0.8% | ||
| Q4 24 | 2.5% | 1.3% | ||
| Q3 24 | 2.7% | 1.8% | ||
| Q2 24 | 1.7% | 0.7% |
| Q1 26 | 3.01× | 1.33× | ||
| Q4 25 | 2.09× | 3.33× | ||
| Q3 25 | 2.88× | 2.17× | ||
| Q2 25 | 0.51× | 2.06× | ||
| Q1 25 | 2.01× | 1.28× | ||
| Q4 24 | 1.17× | 1.96× | ||
| Q3 24 | 1.44× | 2.05× | ||
| Q2 24 | -0.71× | 2.02× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
SSNC
| Technology-enabled services | $1.4B | 85% |
| License, maintenance and related | $239.8M | 15% |
